Skip to Content

Frequently Searched

Supported by

Oncolytics Today Fall 2025

Published Date: October 14, 2025

Feature Articles

Oncolytics Today

Changes Under One Big Beautiful Bill Act May Not Be So Beautiful For Oncology 

Last Updated: 10/06/2025

Oncolytics Today

NCODA Oncology Institute: Understanding the Ecosystem of Access and Distribution

Last Updated: 10/06/2025

Oncolytics Today

The Challenge of Patient Enrollment in Clinical Trials

Last Updated: 10/14/2025

Oncolytics Today

Advances in ALK Inhibition in Non-Small Cell Lung Cancer

Last Updated: 10/14/2025

7 | ONE BIG BEAUTIFUL BILL ACT: New reforms may not be so beautiful for oncology practices and patients. Download

11 | BUSINESS BEHIND ONCOLOGY: Navigating payers, partnerships and the financial landscape. Download

15 | ARTIFICIAL INTELLIGENCE: The near-term potential of AI remains shrouded in regulatory uncertainty. Download

19 | DRUG PRICING UNDER IRA: New laws promise relief, but will pose a challenge for pharma and patients. Download

23 | MEDICARE PART D MAZE: Education is the key to helping your patients understand the new rules. Download

26 | A BETTER MODEL FOR ONCOLOGY: Experts make the case for expanding OOLD in preference to other distribution models. Download

29 | NGS THERAPY REVIEW: The latest recommendations for NSCLC, colorectal, breast and prostate cancers. Download

37 | THE CHALLENGE OF REMS: IMiD prescription management and the role of the pharmacist. Download

43 | ADVANCES IN ALK INHIBITION: New therapies, resistance mechanisms and emerging strategies in NSCLC. Download

50 | PROSTATE CANCER: Imaging and therapy options from an oncology perspective. Download

54 | A NOVEL SCORING FRAMEWORK: Analyzing and improving access pathways to oral oncology therapies. Download

57 | FINDING FINANCIAL ASSISTANCE: How PAN Foundation helps cancer patients. Download

67-71 | INPATIENT TO OUTPATIENT: A look at how multiple practices are evolving CAR-T, BsAbs & BiTES therapy. Download

76 | BsAbs RECOMMENDATIONS: Tear-out charts for lymphoma, multiple myeloma and other disease states. Download Tear Chart.

84 | PHARMACOGENOMICS: UCSF launches PGx program to enhance safety for gastrointestinal cancer patients. Download

87 | ENHANCING ABIRATERONE: Case series on the effect of low-dose and low-fat diet on the drug’s cost and efficacy. Download

93 | LOVE ON LIFE’S TERMS: Finding the language to support one another during the cancer journey. Download

96 | RAPID TRIAL ACTIVATION: Implications and opportunities for investigational drug service operations. Download

98 | CLINICAL TRIAL CHALLENGES: Improving enrollment through trust and patient-centric development. Download

101-108 | GLOBAL PERSPECTIVE: International oncology reviews and reports from Brazil, Morocco and Japan

117 | THE ROAD WARRIOR: New Jersey pharmacist bike-a-thon rider goes that extra mile for his patients. Download

To Request The Oncolytics Today Media Kit / Rate Card, Contact: partnership@ncoda.org

  • Two issues in Spring (March) and Fall (October)
  • Audience includes 10,000+ Oncology and Urology health professionals
  • Print and digital formats available
  • Multi-ad discounts available

 

ADVERTISE TODAY

 

Read more editions

SORT

The Challenge of Patient Enrollment in Clinical Trials

October 14, 2025
This article dives into why so few cancer patients join clinical trials and how breaking barriers like access, trust, and cost — while making studies more patient-friendly — could open doors to lifesaving treatments

Advances in ALK Inhibition in Non-Small Cell Lung Cancer

October 14, 2025
This article is about the evolving landscape of EGFR-targeted therapy in This article shares how new targeted treatments are changing the outlook for people with ALK-positive lung cancer — offering better brain protection, overcoming drug resistance, and helping patients live longer, healthier lives, highlighting advancements from early TKIs to current combinations like osimertinib and amivantamab.

Oncolytics Today Fall 2025

October 14, 2025
A New Way to Treat Brain Cancer? A Phase 1 clinical trial explored the use of Rhenium (186Re) Obisbemeda (186RNL) for treating recurrent glioma, demonstrating its potential to deliver high radiation doses with minimal toxicity. The promising results, particularly in patients receiving higher doses, set the stage for further evaluation in Phase 2 trials.

Oncolytics Today Spring 2025

April 22, 2025
A New Way to Treat Brain Cancer? A Phase 1 clinical trial explored the use of Rhenium (186Re) Obisbemeda (186RNL) for treating recurrent glioma, demonstrating its potential to deliver high radiation doses with minimal toxicity. The promising results, particularly in patients receiving higher doses, set the stage for further evaluation in Phase 2 trials.

Oncolytics Today Fall 2024

October 1, 2024
THE BISPECIFIC ANTIBODY REVOLUTION: Breakthroughs in research have led to a host of new cellular therapies. In this issue of Oncolytics Today, we take a look at recently approved BsAbs as well as advances in tumor-infiltrating lymphocytes, antibody-drug conjugates and CAR-T therapy.

Oncolytics Today Spring 2024

April 1, 2024
Filling the Diversity Gap in Cancer Care: Racial inequity in healthcare, particularly in oncology, has been well-documented. Bringing equity to charitable copay assistance and better communication across diverse healthcare teams offer opportunities to improve the situation.

Oncolytics Today Fall 2023

October 1, 2023
Oncology Faces a Host of Rising Challenges: NCODA takes a hard look at the oncology drug shortage, the Stark Law’s impact on prescription mailing, alternative funding programs, the Inflation Reduction Act and 340B abuse.